A robust body of evidence shows that AD might be sustained by the impairment of insulin signaling in the brain and, therefore, that IR, which is a pathogenetic key aspect of T2D, could be considered a specific target for AD treatment. The gene discussed is INS; the disease is Alzheimer disease.